SCHEMBL23625959

SCHEMBL23625959

CC(C)(C)c1ncnc2c1oc1ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.61
▸ ALDH1A1 P00352 7/20 0.60
▸ PPARG P37231 1/20 0.60
▸ NCOA2 Q15596 1/20 0.60
▸ NCOA1 Q15788 1/20 0.60
▸ LIMK1 P53667 1/20 0.59
▸ MAPT P10636 3/20 0.59
▸ HPGD P15428 6/20 0.54
▸ LMNA P02545 5/20 0.54
▸ NPC1 O15118 4/20 0.54
▸ RAB9A P51151 4/20 0.54
▸ HSD17B10 Q99714 3/20 0.52
▸ KDM4E B2RXH2 2/20 0.52
▸ CASP3 P42574 2/20 0.52
▸ SENP7 Q9BQF6 2/20 0.52
▸ TSHR P16473 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ POLB P06746 2/20 0.51
▸ HRH4 Q9H3N8 1/20 0.51
▸ HTT P42858 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16406269 0.78 SMN1; SMN2 (0.67) SMN1; SMN2ALDH1A1PPARGNCOA2NCOA1
SCHEMBL19161213 0.76 LMNA (0.55) SMN1; SMN2ALDH1A1MAPTHPGDLMNA
SCHEMBL29989707 0.76 SMN1; SMN2 (1.00) SMN1; SMN2ALDH1A1PPARGNCOA2NCOA1
SCHEMBL4539658 0.76 SMN1; SMN2 (1.00) SMN1; SMN2ALDH1A1PPARGNCOA2NCOA1
SCHEMBL25485328 0.76 SMN1; SMN2 (0.69) SMN1; SMN2ALDH1A1PPARGNCOA2NCOA1
SCHEMBL15746035 0.75 ALDH1A1 (0.39) SMN1; SMN2ALDH1A1PPARGNCOA2NCOA1
SCHEMBL25016487 0.75 KDM4E (0.47) SMN1; SMN2ALDH1A1LIMK1MAPTHPGD
SCHEMBL22872914 0.75 SMN1; SMN2 (0.67) SMN1; SMN2ALDH1A1PPARGNCOA2NCOA1
SCHEMBL4436186 0.75 LIMK1 (1.00) SMN1; SMN2ALDH1A1PPARGNCOA2NCOA1
SCHEMBL23877250 0.74 ALDH1A1 (0.64) SMN1; SMN2ALDH1A1PPARGNCOA2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192669-A1 COMPOUND, ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) 2023-06-22 — — US disclosed
US-20230192669-A1 COMPOUND, ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) 2023-06-22 — — US disclosed
WO-2021135181-A1 NITROGEN-CONTAINING COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC DEVICE 陕西莱特光电材料股份有限公司 2021-07-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192669-A1 COMPOUND, ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPARATUS ACHE, OR51E2, L1CAM SMN1; SMN2 1669/4885ALDH1A1 213/4885PPARG 3353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback